[Expert consensus on pre-treatment of clinical samples by liquid chromatography-tandem mass spectrometry].

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) combines the advantages of high separation ability of chromatography and high selectivity, specificity and sensitivity of mass spectrometry, making it one of the most vibrant new technologies in the field of clinical testing. However, the analytical performance is often limited by the characteristics of the sample to be measured. Due to the limited anti-contamination capability of the mass spectrometer, biological samples need to be properly pre-processed to effectively improve the detection performance and achieve accurate detection. The main function of pre-treatment is to selectively separate the target analyte from the biological matrix to reduce interference from other matrix components. At the same time, the target analytes can be concentrated and enriched to improve the analytical sensitivity. At present, there are many kinds of clinical sample pre-treatment methods, and several methods are time-consuming and cumbersome, which brings difficulties to laboratory personnel in method selection, development and standardized operation. Therefore, the purpose of this consensus is to provide guidance for the establishment of laboratory methods and facilitate the standardized development of clinical mass spectrometry measurement.液相色谱-串联质谱法（LC-MS/MS）集色谱技术的高分离能力和质谱技术的高选择性、高特异性及高灵敏性的优点于一体，成为临床检验领域最具有生命力的新技术之一，但其分析效果往往受待测样品特性制约。由于质谱仪的抗干扰能力有限，生物样本多需要进行合适的样品前处理才能有效提高检测性能，实现精准检测。前处理的主要作用是将目标分析物从生物基质中有选择性地分离出来，减少其他基质组分的干扰。同时，还可将目标分析物浓缩和富集，提高检测灵敏度。目前，临床样本前处理方法不仅种类多，个别方法耗时繁琐，给实验室人员在方法选择和开发及标准化操作等方面带来了困难。因此，本共识旨在为实验室方法建立提供指导，助力临床质谱检测方法的研发规范发展。.